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Abstract
Background: Previous studies suggest that human RAD9  (hRad9), encoding a DNA damage
checkpoint molecule, which is frequently amplified in epithelial tumor cells of breast, lung, head and
neck cancer, participates in regulation of the tumor suppressor p53-dependent transactivation of
pro-survival P21WAF1. This study examined the exact mechanism of the hRad9 function, especially
through the phosphorylation of the C-terminus, in the transcription regulation of P21WAF1.
Results: The transfection of phosphorylation-defective hRAD9 mutants of C-terminus resulted in
reduction of the p53-dependent P21WAF1 transactivation; the knockdown of total hRad9 elicited an
increased P21WAF1 mRNA expression. Immunoprecipitation and a ChIP assay showed that hRad9
and p53 formed a complex and both were associated with two p53-consensus DNA-binding
sequences in the 5' region of P21WAF1 gene. The association was reduced in the experiment of
phosphorylation-defective hRAD9 mutants.
Conclusion: The present study indicates the direct involvement of hRad9 in the p53-dependent
P21WAF1 transcriptional mechanism, presumably via the phosphorylation sites, and alterations of the
hRad9 pathway might therefore contribute to the perturbation of checkpoint activation in cancer
cells.
Background
DNA damage checkpoints are signal transduction path-
ways that maintain the proper order of cell cycle events.
When DNA is damaged or perturbed during replication,
the cells respond by the activation of evolutionarily con-
served signal transduction pathways that delay the pro-
gression of the cell cycle and induce repair of the damaged
DNA. These signal transduction pathways include protein
sensors that recognize aberrant DNA structures and acti-
vate kinases, thereby inducing phosphorylation cascades
that ultimately lead to cell cycle arrest and DNA repair
[1,2]. Failure of this cell cycle surveillance mechanism can
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cause genomic instability which eventually leads to the
formation of cancer in mammals [3].
hRad9 protein is the human homologue of Schizosaccharo-
myces pombe Rad9, a member of the checkpoint rad genes
(rad1+, rad3+, rad9+, rad17+, rad26+, and hus1+) which
are required for the S phase (DNA replication) and G2
(DNA mitosis) check points [4,5]. Like its yeast counter-
part, hRad9 forms a ring-shaped, heterotrimeric complex
with the hRad1 and hHus1 proteins [6,7]. Each member
of hRad9-hRad1-hHus1 complex (also known as the 9-1-
1 complex), shares sequence homology with proliferating
cell nuclear antigen (PCNA), a homotrimer that encircles
the DNA and tethers DNA polymerase δ during DNA syn-
thesis [7-10]. PCNA is loaded onto DNA by the penta-
meric protein complex replication factor C (RFC) [11],
which is composed of one large subunit and four smaller
subunits. In a manner analogous to PCNA and RFC, 9-1-
1 complex is loaded onto DNA by a complex between
hRad17 and the four small subunits of RFC [12]. Since
DNA damage induces hRad17-dependent association of
9-1-1 complex with chromatin, the 9-1-1 complex is
believed to be involved in the direct recognition of DNA
lesions during the initial stages of the checkpoint
response; the 9-1-1 complex may thus be associated with
chromatin following DNA damage to transduce signals
for DNA damage-activated checkpoint signaling pathways
[13]. In mammalian cells, the signal initiated by the sen-
sors, two phosphatidylinositol 3-kinase-related kinases
(PIKK), ataxia-telangiectasia mutated (ATM) and ataxia-
telangiectasia mutated and Rad3-related (ATR), plays a
central role in the checkpoint signaling pathways [14].
ATM and ATR are activated by downstream signaling pro-
teins, genotoxins and phosphorylation including Chk1
and Chk2, two protein kinases that regulate checkpoint
responses [15-17]. hRad9 is highly modified by phospho-
rylation in at specific points of the cell cycle after DNA
damage, and it also plays a critical role in checkpoint sig-
naling [18]. ATM-mediated phosphorylation at Ser-272 of
hRad9 is required for IR-induced G1/S checkpoint activa-
tion [19,20]; Other phosphorylation sites in the C-termi-
nal region are also essential for Chk1 activation following
hydroxyurea (HU), IR, and UV treatment [20], although
the exact function of hRad9 in cell cycle control has not
yet been completely characterized.
The tumor suppressor gene TP53 controls cell cycle check-
points, apoptosis, and genomic stability [21]. A defect in
the pathway, involving p53, is essential for the malignant
progression of cancer [22]. When cells with wild-type
TP53 are exposed to DNA-damaging agents, p53 is func-
tionally activated, p53 protein level rises, and p53 binds
to and transcriptionally activates the promoters of target
genes [21,23,24]. These target genes include; P21, MDM2,
GADD45, BAX, IGF-BP3 and CYCLIN G. The P21 gene
product was originally identified, as a potential target for
the p53 tumor suppressive activity (WAF1) [25]. It is
either an inhibitor of the G1 cyclin-dependent kinases
(Cip1) [26], or an inhibitor of DNA synthesis that is
expressed during cellular senescence (SDI1) [27]. It is
known that p21 is a major effector of the G1 cell cycle
checkpoint. Therefore, p53 is a negative regulator of the
cell cycle progression and it controls the transition from
G1 to S phase of the cell cycle [28]. This report demon-
strates that hRad9 plays a role in the modulation of P21
transcription by direct interaction with p53. Furthermore,
the substitution of the phosphorylation sites on hRad9 to
Ala resulted in an alteration of the regulation of P21. The
present study supports the hypothesis that hRad9 plays a
role in the modulation of P21 transcription, presumably
via competition with p53, that involves its C-terminus,
which would be essential for the cellular response to DNA
damage.
Results and discussion
P21 is activated immediately after UV treatment
Several previous studies have shown that genotoxic stress
induces the stabilization and transient accumulation of
wild-type p53 protein in mammalian cells, leading to an
increase of expression of p53 down-stream genes, includ-
ing  P21  [21,25]. Employing RT-PCR, the level of P21
mRNA expression of human embryonic kidney 293 cells
was examined in these experiments. The level of P21
mRNA expression substantially increased at 30 min after
UV irradiation and reached maximal levels at 1 hr thereaf-
ter. At that time, the mRNA levels were reduced but still
detectable until 72 hr after UV exposure (Fig. 1A). Next,
using the protein equivalent to each time points, a West-
ern blotting analysis was performed to examine the time
course of p21 protein expression. As shown in Figure 1B,
a substantial increase of p21 was seen at 3, 12, and 24 hr
following exposure to UV. These results indicate that the
accumulation of both P21  transcript and p21 protein
occurred, and G1/S checkpoint was activated after UV irra-
diation. Since 293 cells are immortalized by E1B, derived
from human adenoviral proteins, and might be defective
in p53 signaling, another MRC5 fibroblast cell line with
wild-type p53 was examined, and observed that P21
mRNA increased about 3.3 fold after UV irradiation
(Additional file 1), thus suggesting that exposure to UV
leads an increase of P21 expression of both cell lines sim-
ilarly under these conditions. This expression pattern of
P21 mRNA and p21 protein suggests that the G1/S check-
point is activated immediately after DNA damage, and
inhibits damaged cells from progressing through the cell
cycle and entering the S phase [29]. After the peak of acti-
vation, P21 transcription declined as observed in a recent
report that indicated that p21 can be degraded during
excision repair [30]. This suggests that more than the
arrest of the cell cycle at G1 or a broad time period couldBMC Molecular Biology 2007, 8:37 http://www.biomedcentral.com/1471-2199/8/37
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thus be involved in the decrease of P21 mRNA and protein
following UV exposure.
The role of hRad9 in p53-dependent P21 activation 
through its C-terminus
Utilizing the P21 promoter-luciferase reporter system, the
functional aspect of regulation of P21  by hRad9 was
assessed. Since phosphorylation of hRad9 is required for
DNA damage checkpoint activation [20], the requirement
of phosphorylation of hRad9 for P21 transcription was
investigated using wild-type and the following phosphor-
ylation-defective RAD9 mutants: 1) RAD9-S272A, with a
substitution of Ser-272 with an Ala residue, 2) RAD9-9A,
with substitutions of C-terminus phosphorylation sites
including Ser-272, Ser-277, Ser-328, Ser-336, Ser-341, Ser-
355, Ser-375, Ser-380, and Ser-387, with Ala, and 3)
RAD9-8A, with substitutions of all C-terminus phosphor-
ylation sites except for Ser-272, with Ala. Western blotting
was performed to confirm the expression of the protein in
wild-type and mutants,. Wild-type Rad9 was detectably
expressed as a series of large proteins, suggesting the phos-
phorylated form(s) of hRad9 (Fig. 2A, lane 2) [18]. Rad9-
S272A also expressed with a similar series of large pro-
teins, presumably corresponding to different phosphor-
ylated species of hRad9, with a gradient of
phosphorylation excluding the Ser272 residue. (Fig. 2A,
lane 3) [18]. The transfection of RAD9-8A or RAD9-9A
resulted in a reduced phosphorylation compared to wild-
type Rad9 (Fig. 2A, lanes 4 and 5, compared with lane 2).
The results indicate that phosphorylation-defective
mutants are substantially expressed and retain the capac-
ity for reduced phosphorylation [18]. Afterward, the pro-
moter region of P21  was fused to a luciferase reporter
(WWP-Luc-P21 promoter) and it was cotransfected along
with plasmids into cells as indicated. Background levels of
expression were low, as demonstrated by a control trans-
fection of empty vector and promoter-less pGL3-basic
(Fig. 2B, column 1). By using the reporter vector, contain-
ing the p53-binding consensus sequence [31], the intro-
duction of p53 expectedly induced luciferase activity (Fig.
2B, column 7). The introduction of the wild-type Rad9
also induced the positive luciferase activity (Fig. 2B, col-
umn 3), although not as intensively as p53. The co-expres-
sion of p53 and wild-type Rad9 induced luciferase activity
(Fig. 2B, column 8) at an intermediate level in compari-
son to that seen when each protein is transfected inde-
pendently. Considering these data, in association with the
previous report of the potential transactivating property of
hRad9 for the P21 promoter [32], these results support the
concept that hRad9 can stimulate the transcription of P21
and it may modulate the p53 function. The luciferase
activity was comparable among wild-type and phosphor-
ylation-defective mutants following the plasmid introduc-
tion (Fig. 2B, columns 4 to 6, compared with 3), and was
lower in the co-expression of mutants (Fig. 2B, columns 9
to 11, compared with 8), suggesting that the phosphoryla-
tion of hRad9 is involved in regulation of p53-dependent
P21 transcription. Yin et al. [32] reported that wild-type
hRad9 activates P21 transcription and that the co-expres-
sion of p53 and wild-type hRad9 results in the intermedi-
ate transcriptional activity by p53 or hRad9 alone,
consistent with the present results. This suggests that
phosphorylation may thus play a possible role in p53
dependent P21 transcription.
Knock down of endogenous hRad9 increases the 
transcription of P21
Endogenous hRad9 was knocked down using siRNA to
address the role of hRad9 for the transcription of P21 in
UV-induced effect on the expression of P21 mRNA and p21  protein Figure 1
UV-induced effect on the expression of P21 mRNA 
and p21 protein. 293 cells were exposed to UV at 20 J/m2 
and harvested 0 to 72 hr after treatment as indicated. Data 
represent the means ± SD of three independent experi-
ments. (A) The time course of P21 mRNA expression. RNA 
was extracted for RT-PCR. The ratios of P21 mRNA to 
G3PDH mRNA were measured with densitometry. (B) The 
time course of p21 protein expression. Cell lysates were 
extracted and separated by SDS-PAGE, transferred to a 
nitrocellulose membrane, and probed with anti-p21 antibody. 
The signal intensity of the Western blotting is shown.
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response to UV exposure. A Western blot analysis showed
that siRNA treatment resulted in the reduction of endog-
enous p53 or hRad9 (Fig. 3A). In addition, hRad9 siRNA
did not increase p53 protein compared to mock treatment
(Fig. 3B). Using RT-PCR, the P21 mRNA level was deter-
mined. The knockdown of hRAD9 resulted in an increase
in the level of P21 mRNA (Fig. 3C, column 3), whereas the
knockdown of TP53 showed levels of P21 mRNA compa-
rable to mock-treatment (Fig. 3C, column 2, compared
with 1). This suggests that hRad9 plays a role in modulat-
ing P21 transactivation. After UV treatment, the mock-
treated cells showed an increase of P21 mRNA (Fig. 3C,
column 4), compared with UV (-) control, under these
conditions. TP53 siRNA transfection resulted in an obvi-
ous reduction of P21 mRNA (Fig. 3C, column 5), thus sug-
gesting that the effect of p53 reduction was appreciable
after UV-induced damage under those conditions. In con-
trast, hRAD9 knockdown resulted in an apparent increase
of P21 mRNA after UV exposure (Fig. 3C, column 6). The
UV treatment was not simply additive to the hRAD9
knockdown in P21 transactivation, thus suggesting that
the reduction of endogenous hRad9 resulted in a pro-
found effect in UV damage-dependent and -independent
P21 pathway. Furthermore, semi-quantitative RT-PCR and
PCR-Southern blotting was performed to confirm the
effect of Rad9 siRNA, and similar results were obtained
(Additional files 2A and 2B). Using TP53-deficient MEFs,
real time RT-PCR was used to confirm the effect of knock-
down of Rad9 in P21 transcription, and this demonstrated
an increase in P21 mRNA after knockdown of Rad9 (Addi-
tional file 2C), thus supporting the concept that Rad9 is
not only an activator, but also a modulator in this path-
way. The transactivation of P21 in the absence and reduc-
tion of the p53 and Rad9 may be due to transcription
factors, such as sp1 [33]. In addition, a p53-deficient cell
line TE-7, with transcriptionally inactive TP53 [34], was
used to study the effect of the introduced hRad9 and p53
proteins under p53 negative background. TE-7 cells were
transfected with wild-type or phosphorylation-defective
mutant RAD9, and TP53 plasmids, and the expression of
each protein was confirmed by Western blotting; the exog-
enous expression of wild-type and mutant RAD9 elicited
the induction of P21 mRNA and its product, associated
with Ser15 phosphorylation of transfected p53, whereas
endogenous p53 and its phosphorylated form were unde-
tectable without transgene introduction (Additional file
3A, 3B, and data not shown), thus suggesting that Rad9
may play a role in the p53-dependent p21 transactivation
and Rad9-p53 might express a certain active function in
p53 negative cancer cells, compatible with the previous
report [32]. One might speculate that Rad9-p53 has a high
affinity for the p21 promoter; rather than the induction of
p21, the transfection could result in the reduction of p21
in endogenous p53-positive cells, and might stimulate
p21 in p53-negative background. It also should be noted
that numerous or uncharacterized, additional alterations
might accumulate in cancer-derived cell lines. Taken
together, the present data indicate that the transfection of
hRad9 plays a role in P21 transcription, depending on the
co-expressed p53 (Fig. 2), and the knockdown of hRad9
can stimulate P21 transactivation, thus suggesting that the
protein level of hRad9 may be involved in modulation
and regulation of P21 transactivation. Considering that
other studies show that hRad9 accumulation after DNA
damage [12,13] may enhance the modulation of P21 pro-
moter activation, this supports the hypothesis that hRad9
may regulate P21 transcription in concert with p53, and
that the reduction of hRad9 might elicit the checkpoint
Effect of wild-type and phosphorylation-defective hRad9  mutants expression on P21 transactivation Figure 2
Effect of wild-type and phosphorylation-defective 
hRad9 mutants expression on P21 transactivation. (A) 
Western blots of lysates from 293 transfectants of wild-type 
or phosphorylation-defective RAD9 mutants. Lysates were 
analyzed by Western blotting, probed with anti-Rad9 (top), 
anti-FLAG (middle), or anti-actin (bottom) antibody. (B) P21 
transcription assay with wild-type and phosphorylation-
defective RAD9. mutants using P21 promoter-luciferase 
reporter system. After transfection into 293 cells, the rela-
tive luciferase activities are shown as the ratios of Firefly to 
Renille. Data represent the means ± SD of four independent 
experiments.
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response. Recent studies with tumors indicate that the
hRAD9 gene is located in a chromosomal region at 11q13.
This genomic region is amplified and both mRNA and
protein are frequently overexpressed in breast, lung, head
and neck cancer [35,36]. This up-regulation is correlated
with tumor size and local recurrence [35]. Furthermore,
silencing hRAD9 by RNA interference inhibits cell prolif-
eration  in vitro [35]. These observations are consistent
with the findings of the present study. Nevertheless, there
is still insufficient data to determine whether hRad9
might be involved directly or indirectly in p53-dependent
P21  activation. Therefore, the assessment of the direct
association of hRad9-p53 is the next step.
hRad9 associates with p53
The data reported above indicate that transfection of
hRad9 modulates p53-dependent P21 promoter activa-
tion, and that knockdown of hRad9 stimulates p53-
dependent P21 promoter activation. Therefore, the associ-
ation of endogenous hRad9 with endogenous p53 was
examined using immunoprecipitation. Endogenous
hRad9 was co-immunoprecipitated with p53 from 293
cells (Fig. 4A). The hRad9-p53 association was then
assessed in another MRC5 cells using immunoprecipita-
tion and similar results were obtained (Additional file 4),
thus suggesting that the association is not specific to the
cell type. Considering these results, along with those of
the pull-down assay of GST-fusion p53 with [35S] methio-
nine-labeled in vitro-translated hRad9 protein (data not
shown), the findings of the present study strongly suggests
that hRad9 acts as a modulator of P21  transcription
through a direct association with p53. To investigate
whether phosphorylation of hRad9 affects the binding to
p53, wild-type or phosphorylation-defective RAD9
mutants were transfected, and immunoprecipitation was
performed. The results showed p53 to be associated with
hRad9, in both the wild-type and phosphorylation-defec-
tive mutants (RAD9-S272A,  RAD9-8A, and RAD9-9A).
However the association with RAD9-8A or RAD9-9A was
somewhat reduced (Fig. 4B). The data implicate the sub-
stantial association of p53 with intact hRad9, and that the
hRad9 mutants might be altered in capacity for p53 bind-
ing, presumably due to conformational changes and affin-
ity of complex, which would result the release of
immunoprecipitated components after extensive washes.
Previous studies have showed that p53 protein can be
phosphorylated at Ser-15 within 1 hr after DNA damage
[37]. A Western blot analysis indicated that Ser-15 of p53
was phosphorylated 5 min after UV treatment in the
present experiments (Fig. 4C). The time course of this
reaction was examined to determine whether the associa-
tion of hRad9 and p53 might be altered after UV irradia-
tion. Figure 4D demonstrates that the phosphorylation of
p53 at Ser-15 in the immunoprecipitated components
increased at 5 min and reached a maximal level at 6 hr
after UV treatment, and declined, consistent with the
Western blot findings in Figure 4C, whereas the total
amount of Rad9-p53 interaction did not increase. In addi-
tion, other phosphorylation sites of p53, including Ser-6,
Ser-9, Ser-20, Ser-37, Ser-46, and Ser-392 were also exam-
ined and they were phosphorylated temporally, regardless
of the positive association of hRad9 with p53 over the
time course, as observed Ser-15 (Fig. 4D, and data not
shown). These results indicate that the binding of hRad9
and p53 is not significantly affected by phosphorylation,
Knockdown experiment of hRad9 and p53 using siRNAs Figure 3
Knockdown experiment of hRad9 and p53 using siR-
NAs. (A) hRad9 and p53 expression after transfection with 
hRAD9 (siRad9) or TP53 siRNA (siP53). The signals of immu-
noblots were measured with a densitometer, and the ratios 
of hRad9 or p53 to actin control were depicted in the figure. 
(B) p53 expression after transfection with hRAD9 (siRad9) or 
TP53 siRNA (siP53). (C) Alteration of P21 mRNA expression 
in the knockdown experiment by hRAD9 or TP53 siRNA. 
Cells were treated with hRAD9 (siRad9) or TP53 siRNA 
(siP53) and subjected to UV exposure or mock treatment. 
The cells were harvested and RNAs were extracted for RT-
PCR with P21 primers. The relative amount of P21 mRNA to 
G3PDH mRNA is shown. Data represent the means ± SD of 
three independent experiments.
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though it is possible that the modifications of the phos-
phorylation in these amino acid residues are not involved
in the binding of the components.
The present immunoprecipitation study revealed hRad9
to be associated with p53, and the association was
detected regardless of degree of phosphorylation of p53
and presumably of hRad9. A previous report also demon-
strated that constitutive phosphorylation of hRad9 does
not influence the stability of the 9-1-1 complex [20]. It is
suggested that hRad9, as a complex with p53, may be
involved in the transactivation of P21 and that the phos-
phorylations of hRad9 and p53 might modulate the trans-
activation activity of the complex. Whereas none of the
phosphorylation sites of hRad9 targeted in the present
study have been previously reported to be required for
genotoxin-induced chromatin binding [20], the present
data suggest that hRad9 phosphorylation might be
involved in binding affinity for p53-consensus binding
sites.
Phosphorylation of hRad9 affects the preference of p53 
for binding sites
The effects of alterations of the affinity of hRad9/p53 for
p53-consensus binding sites of P21 promoter for chroma-
tin remodeling after UV treatment were investigated. Pre-
vious studies show that hRad9 specifically binds to a p53-
consensus DNA-binding sequence in the P21 promoter
and regulates P21 at the transcriptional level [32]. A ChIP
assay was used to evaluate whether the affinity of hRad9/
p53 complex for p53 binding sites may increase after UV
treatment, and whether the phosphorylation of hRad9
affects the affinity for binding sites. The human P21 pro-
moter contains two p53-binding sites (Fig. 5A), and the
treatment with 5-fluorouracil significantly enhances the
recruitment of p53 protein to both upstream and down-
stream P21 promoter regions [33]. Therefore, each of the
two p53-binding sites was observed. A ChIP assay with
anti-p53 and anti-Rad9 antibodies showed that their
binding to each of upstream and downstream P21 pro-
moters was increased 15 to 30 min after UV treatment,
whereas ChIP with anti-acethylated histone H4 antibody
indicated that the acetylation around the P21 promoter
was not altered significantly in the those conditions (Fig.
5B), thus suggesting that the association of p53 and
hRad9, and its subsequent complex with P21 promoters is
correlated with the regulation of transcription after UV
exposure. Next, ChIP assays were performed with trans-
fectants of the wild-type or phosphorylation-defective
RAD9 plasmids. As shown in Figure 5C, hRad9 and p53
binding to the downstream site was inhibited by introduc-
tion of phosphorylation-defective mutants (as shown as
asterisks). The association was increased after UV treat-
ment, in all cases except for cells transfected with the
RAD9-8A plasmid which showed a low affinity to the
Interaction between hRad9 and p53 Figure 4
Interaction between hRad9 and p53. (A) Endogenous 
association of hRad9 and p53. Immunoprecipitation and 
Western blot analysis were performed using lysates of 293 
cells. Anti-c-kit antibody was used as a negative control. (B) 
Immunoprecipitation using cell lysates of 293 transfectants 
with FLAG-tagged wild-type or phosphorylation-defective 
RAD9 plasmids. Each cell lysate was immunoprecipitated with 
anti-FLAG antibody and immunoblotted with anti-p53 (top) 
or anti-FLAG (bottom) antibody. HC, IgG heavy chain of the 
anti-FLAG antibody. (C) The time course experiment for the 
accumulation of phosphorylated p53 at Ser-15 after UV. 293 
cells were exposed to UV at 20 J/m2 and harvested 0 to 72 hr 
after treatment as indicated. A Western blot analysis was 
performed using anti-phosphorylated p53 (Ser-15) antibody. 
Relative expression of phosphorylated p53 to whole p53 is 
shown. Data represent the means ± SD of three independent 
experiments. (D) The time course experiment of hRad9/p53 
complex formation after exposure to UV. 293 cells were 
exposed to UV at 20 J/m2 and harvested 0 to 72 hr after 
treatment. Top, immunoprecipitation with anti-p53 antibody 
and Western blot analysis using anti-Rad9 antibody; middle, 
immunoprecipitation with anti-Rad9 antibody and Western 
blot with anti-p53 antibody; bottom, immunoprecipitation 
with anti-Rad9 antibody and Western blot with anti-phos-
phorylated p53 (Ser-15) antibody.
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binding site. This suggests the possibility that systematic,
scheduled or sequential phosphorylation of Ser residues
in hRad9 might be necessary for efficient binding to p53-
consensus DNA sequences. ChIP binding of hRad9 seems
to be reduced slightly, compared to that of p53, which
might be due to the specificity of the antibodies. Similar
results with hRad9 and p53 were obtained at the upstream
binding site (Fig. 5D). The present results suggest that the
phosphorylation of the C-terminal region of hRad9 may
play a role in modulation of the affinity for binding its
consensus sites.
Recent studies have demonstrated the multifunctional
roles of hRad9 a DNA damage sensor in the 9-1-1 com-
plex, a G2/M checkpoint via the phosphorylation of
Chk1, in DNA repair via DNA polymerase β [38] or flap
endonuclease 1 [39], and in apoptosis via potential bind-
ing to Bcl-2 or Bcl-xL [40]. The present study, demon-
strated the direct association of Rad9-p53 and the
regulatory role of phosphorylation in the activation of
P21 transcription, thus indicating that hRad9 is an impor-
tant modulator, but not a unique player with a single
function.
Conclusion
hRad9 has a complex role in response to DNA damage,
acting not only as an activator but also as a modulator in
P21 transcription and contributing to the regulation of
genomic integrity. If hRad9 was regulated inaccurately,
the P21 could not regulate the appropriate G1/S transition
and replication, thus resulting in the occurrence of
unscheduled replications after DNA damage. Such events
can contribute to the accumulation of pathological condi-
tions and genomic instability in carcinogenesis and tumor
progression.
Methods
Cell culture
Human embryonic kidney 293 cells, immortalized by E1B
protein, derived from a part of the human adenovirus,
and MRC5 fibroblasts with wild-type p53 status were cul-
tured in DMEM with 10% fetal cow serum (FCS). TE-7 cell
line derived from human esophageal cancers, which p53
is inactivated by transcriptional repression [34], was used.
Murine embryonic fibroblast (MEF) cell lines were
obtained from TP53-deficient and control wild-type mice
(Jackson Laboratory). After pairs of mice were mated,
MEFs obtained from sub-cutaneous tissue of embryos at
13.5 post-coital days were grown in DMEM medium with
20% FBS. Cells were transfected with 3 ug of expression
plasmid of siRNA to inhibit Rad9 (pBAsi-mU6 plasmid,
TAKARA, sequence in Table 1), selected in medium with 1
ug/ml puromycin. For exposure to UV, 60% to 70% con-
fluent monolayer cells were washed and irradiated with
UVC emitted by germicidal lamps (GL-15; NIPPO Elec-
tronic). Irradiation dose was measured with a digital UV-
C densitometer (UCV-254; Custom). Control cells were
taken into the UV exposure source but were not irradiated.
UV exposure-dependent increase of the hRad9 association  to the p53-binding site in the P21 promoter Figure 5
UV exposure-dependent increase of the hRad9 asso-
ciation to the p53-binding site in the P21 promoter. 
(A) Schematic representation of the P21 promoter showing 
the location of the oligonucleotide primer sets, utilized in the 
ChIP assays. (B) ChIP assay with anti-p53 antibody, anti-
acetylated histone H4 antibody or anti-Rad9 antibody for 
upstream (left) and downstream (right) P21 promoter sites. 
293 cells were harvested with or without exposure to UV. 
ChIP assays were performed using anti-p53 (p53) or anti-
acetylated histone H4 antibody (Ac-H4). Anti-c-kit antibody 
was used as a negative control. (C) ChIP assay for the down-
stream P21 promoter site. 293 cells were transfected with 
wild-type or phosphorylation-defective RAD9 plasmids, and 
harvested before and after exposure to UV. ChIP assays 
were performed with anti-Rad9 (left) or anti-p53 antibody 
(right). The relative intensity of signals of immunoprecipitated 
DNA to input DNA was measured with densitometry. Data 
represent the means ± SD of three independent experi-
ments. (D) ChIP assay for the upstream P21 promoter site. 
ChIP assays were performed with anti-Rad9 (left) or anti-p53 
antibody (right) for P21 promoter upstream-binding site. 
Data represent the means ± SD of three independent exper-
iments.
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Antibodies and plasmids
The following antibodies were used: anti-Rad9 (Alexis),
anti-p53 (BD Transduction Laboratories), anti-acetylated
histone H4 (Upstate Biotechnology), anti-FLAG (Sigma-
Aldrich), and anti-phosphorylated p53 (Ser-15) antibody
(Cell Signaling Technology).
We used the wild-type RAD9 plasmid and the phosphor-
ylation-defective RAD9 mutants, kindly given from Dr. L.
M. Karnitz [20]. To construct FLAG-tagged RAD9 expres-
sion plasmids, the DNAs were amplified by the PCR
method with the advantage Clontaq system with high
fidelity (Clontech) according to the manufacture's
instruction, by using wild-type and RAD9 mutant vectors
as templates and a set of primers (Table 1). The amplified
products were separated by the electrophoresis, cut and
purified with gel purification kit (Qiagen). After digestion
with NotI and XbaI, the samples were ligated to the clon-
ing site of pcDNA3.1-FLAG vector. WWP-Luc-P21  pro-
moter vector, kindly given from Dr. B. Vogelstein [25],
pcDNA-TP53 expression plasmid, kindly given from Dr. J.
Yokota [41].
Transfection
Plasmids were transfected with LipofectAMINE2000
according to manufacturer's instructions (Invitrogen).
Double-stranded siRNAs for hRAD9  and  TP53  (Santa
Cruz Biotechnology) were transfected twice 24 h apart
using TransIT-TKO transfection reagent (Mirus).
Reverse transcription (RT)-PCR and real time PCR
RNA was extracted using ISOGEN protocol (Nippon
Gene). First-strand cDNA was prepared from total RNA (5
μg) and oligo (dT) using the Superscript First-Strand Syn-
thesis System (Invitrogen). The synthesized cDNA was
amplified by PCR. The oligonucleotides used were shown
in Table 1[42,43]. The PCR conditions were: for P21, an
initial denaturation at 94°C for 1 min, followed by 37
cycles of 94°C for 8 sec, 53°C for 30 sec, and 72°C for 1
min; for G3PDH, the denaturation at 94°C for 1 min, fol-
lowed by 28 cycles of 94°C for 10 sec, 60°C for 15 sec,
and 72°C for 1 min. PCR products were separated by elec-
trophoresis and visualized by ethidium bromide staining.
The intensity of each band corresponding to PCR was
quantified by densitometry analysis (Quantity One, BIO-
RAD). The negative control without RTase showed no
amplifications. Each experiment was repeated at least
thrice. PCR-Southern blot analysis was performed as
described [44], with minor modifications. Briefly, after
four different cycles (24, 28, 32 and 36) of PCR, reactions
(20 ul) in separate tubes were subjected to electrophore-
sis, transferred to nylon filter and were hybridized with
[32P] dCTP-labeled P21  or  G3PDH  probe, which was
amplified by RT-PCR. After washes, filter was exposed on
x-ray film. For Real time RT-PCR assessment of P21
expression, total RNA was extracted and cDNA was syn-
thesized. Primers and TaqMan probe were used for ampli-
fication and assessment according to the manufacture's
instruction (Mm00432448_m1, Applied Biosystems).
Protein study
For Western blotting, cells were extracted with lysis buffer
[20 mM Tris-Hcl (PH 7.4), 1% Triton × 100, 10% glycerol,
and 0.1 mM PMSF]. The cleared extracts were resolved by
SDS-PAGE, and transferred to polyvinylidene difluoride
membrane. Immunoblotting was performed by standards
methods and signal was detected enhanced chemilumi-
nescence system (ECL, Amarsham Biosciences). The
intensity of each band was quantified by densitometry
analysis (Quantity One, BIO-RAD). For immunoprecipi-
tation (IP), cells were harvested with IP-lysis buffer [25
mM Tris-HCl (PH 7.5), 0.2% NP40, 250 mM NaCl, and 1
mM EDTA] and 500 μg of cell lysates, after being pre-
cleared with protein G-Sepharose beads, were incubated
with 3 μg of specific antibody overnight. Antigen-anti-
body complex was immobilized on protein G-Sepharose
beads, and washed five times in lysis buffer. Bound pro-
teins were eluted by boiling and subjected to SDS-PAGE
and immunoblotting.
Promoter study
For luciferase reporter assay, transfected cells were cul-
tured in a complete growth medium for 24 h and har-
vested, performed according to the manufacture's
Table 1: Primers and Probes for Each Experiments
Names of Primers and Probes Sequences
Target sequence of pBAsi-mU6 vector (TAKARA; Code: 3225) 5'-CCA CAC TCT TAG AGC AAG A-3'
PCR primers for wild-type and RAD9 mutants 5'-AAA AGC GGC CGC GCA TGA AGT GCC TGG TCA CGG G-3' 
and 5'-TTT TCT AGA TCA GCC TTC ACC CTC ACT GTC-3'
RT-PCR primers for P21 corresponding to an amplified product of 335 bp 5'-ACC CTC TCA TGC TCC AGG T-3' and 5'-CCT TGT TCC GCT 
GCT AAT CA-3'
RT-PCR primers for glyceraldehydes-3-phosphate dehydrogenase (G3PDH), to an amplified product 
of 451 bp product
5'-ACC ACA GTC CAT GCC ATC AC-3' and 5'-TCC ACC ACC 
CTG TTG CTG TA-3'
ChIP primers for human P21 downstream promoter 5'-GAG GTC AGC TGC GTT AGA GG-3' and 5'-TGC AGA GGA 
TGG ATT GTT CA-3'
ChIP primers for human P21 upstream promoter 5'-CCT ATG CTG CCT GCT TCC CAG GAA-3' and 5'-TAG CCA 
CCA GCC TCT TCT ATG CCA G-3'BMC Molecular Biology 2007, 8:37 http://www.biomedcentral.com/1471-2199/8/37
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instruction (Promega). Each plasmids including empty
expression vector were transfected with the same amounts
(60 ng). Luciferase activity was measured on a Fluoroskan
Ascent FL Luminometer (Thermo Labsystems Oy). As the
internal control, each sample was co-transfected with
pRL-TK, and the relative luciferase activity was figured out
as the ratio of Firefly to Renille to adjust the tansfection
rates. Each experiment was repeated at least thrice. Chro-
matin immunoprecipitation (ChIP) assay was performed
using the Upstate Biotechnology kit. Briefly, ~1 × 106 cells
were cross-linked with 1% formaldehyde, resuspended in
200 μL of SDS-lysis buffer, and sonicated to disrupt chro-
matin at an average length of 200 to 1,000 bp. After cen-
trifugation, 20 μL of each supernatant were heated at
65°C for 4 h after the addition of 1 μL of 5 M NaCl, which
was used as an input. The rest of the supernatant was
added to 300 μL of ChIP dilution buffer containing 1 μg
of either anti-Rad9 or anti-p53 antibody. After incubation
at 4°C for 16 h, the immunoprecipitates were washed,
eluted, heat treated, and digested with proteinase K. DNA
was recovered by phenol/chloroform extraction and etha-
nol precipitation. We used one tenth (2 μL) of the final
suspension for PCR using primers corresponding to differ-
ent regions of the human P21 promoter. Primers used
were shown in Table 1[33].
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